|
|
Vaccine Detail
|
Innovax-ILT |
| Vaccine Information |
- Vaccine Name: Innovax-ILT
- Target Pathogen: infectious laryngotracheitis virus
- Manufacturer: Merck Animal Health
- Type: Recombinant vector vaccine
- Status: Licensed
- Location Licensed: Europe
- Host Species for Licensed Use: Human
- Preparation: The vaccine was titrated in a secondary chicken embryo fibroblast (CEF) monolayer in 60 mm plates. Ten-fold dilutions of the reconstituted vaccine were produced in Dulbecco’s modified Eagle medium (DMEM), and 200 μL of each dilution was added to three plate replicates. The inoculated cells were incubated at 37 °C and 5% CO2 for 5 days. At day 5 following inoculation, plaques were microscopically counted. Virus titer was calculated and recorded as 6360 plaque forming units (PFU)/per dose. (Loncoman et al., 2018)
- Immunization Route: Intramuscular injection (i.m.)
- Description: Innovax-ILT is a recombinant vector vaccine which uses herpesvirus of turkeys as a vector (Loncoman et al., 2018)
|
| Host Response |
|
|
| References |
|
|
|
